文献速递免疫规划传染病防控与疫情报告

用辛布血清群正布尼亚病毒高度保守的施马伦贝格病毒核蛋白小片段免疫可降低IFNAR-/-小鼠攻毒后的病毒血症

Immunization with a small fragment of the Schmallenberg virus nucleoprotein highly conserved across the Orthobunyaviruses of the Simbu serogroup reduces viremia in SBV challenged IFNAR-/- mice.
PubMed 文献 · Vaccine · 2023-04-19

施马伦贝格病毒(SBV)核蛋白(SBV-N)的N端结构域(Met1-Thr133)及更小片段C4(Met1-Ala58)作为亚单位疫苗原型,两次注射可保护I型干扰素受体敲除(IFNAR-/-)小鼠抵抗强毒SBV攻击,对照组出现严重发病和体重下降。C4与辛布血清群多种病毒核蛋白相应区域序列同源性约87.1%。

要点

  • N端结构域和C4片段两次免疫可保护IFNAR-/-小鼠抵抗SBV攻毒。
  • 对照组攻毒后出现严重发病和体重下降。
  • C4与辛布血清群病毒核蛋白同源性约87.1%,适合纳米颗粒疫苗制剂。

核心结论

  • SBV-N的N端结构域和C4片段可作为亚单位疫苗候选,C4更适合纳米颗粒疫苗制剂并为其他正布尼亚病毒研究铺路。

研究设计与样本

  • 基于SBV-N晶体结构设计截短结构域,以N端结构域(Met1-Thr133)和C4片段(Met1-Ala58)为疫苗原型,在IFNAR-/-小鼠中评价两次注射后的免疫保护。

主要发现

  • 两次注射N端结构域和C4多肽保护IFNAR-/-小鼠抵抗强毒SBV攻击,对照组出现严重发病和体重下降。
  • 病毒血症分析及脾细胞经N端区域再刺激后分泌IFN-γ,支持这两个片段可作为亚单位疫苗。
  • C4多肽与辛布血清群多种病毒核蛋白相应区域序列同源性约87.1%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schmallenberg Virus (SBV), an arbovirus from the Peribunyaviridae family and Orthobunyavirus genus, was discovered in late 2011 in Germany and has been circulating in Europe, Asia and Africa ever since. The virus causes a disease associated with ruminants that includes fever, fetal malformation, drop in milk production, diarrhoea and stillbirths, becoming a burden for small and large farms. Building on previous studies on SBV nucleoprotein (SBV-N) as a promising vaccine candidate, we have investigated the possible protein regions responsible for protection. Based on selective truncation of domains designed from the available crystal structure of the SBV-N, we identified both the N-terminal domain (N-term; Met1 - Thr133) and a smaller fragment within (C4; Met1 - Ala58) as vaccine prototypes. Two injections of the N-term and C4 polypeptides protected mice knockout for type I interferon (IFN) receptors (IFNAR-/-) challenged with virulent SBV, opposite to control groups that presented severe signs of morbidity and weight loss. Viremia analyses along with the presence of IFN-γ secreted from splenocytes re-stimulated with the N-terminal region of the protein corroborate that these two portions of SBV-N can be employed as subunit vaccines. Apart from both proteinaceous fragments being easily produced in bacterial cells, the C4 polypeptide shares a high sequence homology (∼87.1 %) with the corresponding region of nucleoproteins of several viruses of the Simbu serogroup, a group of Orthobunyaviruses that comprises SBV and veterinary pathogens like Akabane virus and human infecting viruses like Oropouche. Thus, we propose that this smaller fragment is better suited for vaccine nanoparticle formulation, and it paves the way to further research with other related Orthobunyaviruses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Guerra GS, Barriales D, Lorenzo G, et al. Immunization with a small fragment of the Schmallenberg virus nucleoprotein highly conserved across the Orthobunyaviruses of the Simbu serogroup reduces viremia in SBV challenged IFNAR-/- mice. Vaccine. 2023. PMID: 37085455. doi:10.1016/j.vaccine.2023.04.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。